BioTuesdays
Check Cap
Markets

Dawson James ups Check-Cap to buy; PT $1

Dawson James Securities upgraded Check-Cap (NASDAQ:CHEK) to “buy” from “neutral” and maintained its price target of $1. The stock closed at 60 cents on Feb. 4. The company’s C-Scan is a colorectal cancer screening test...

February 7, 2022
Inozyme Pharma
Markets

HCW starts Inozyme at buy; PT $33

H.C. Wainwright initiated coverage of Inozyme (NASDAQ:INZY) with a “buy” rating and $33 price target. The stock closed at $6.10 on Feb. 4. Inozyme is a rare disease biopharmaceutical company focused on developing...

February 7, 2022
Fusion
Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022
Markets

Brookline starts IceCure at buy; PT $5.65

Brookline Capital Markets initiated coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $5.65. The stock closed at $2.59 on Feb. 1. IceCure is a commercial-stage medical device company...

February 2, 2022
Markets

Stifel starts Vigil Neuroscience at buy; PT $24

Stifel initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “buy” rating and $24 price target. The stock closed at $12.90 on Jan. 31. Vigil is focused on precision medicine approaches to treat dementia, with a...

February 1, 2022